# Wei Fu

> Wei Fu is a Series B investor at C-Bridge Capital backing Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [C-Bridge Capital](https://shizune.co/investors/profile/c-bridge-capital)
- Location: New York, United States
- Total investments: 7
- Last investment: May 2026
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/wei-fu-38545139/?ppe=1

Wei Fu is a Series B investor at C-Bridge Capital in New York focused on Biotechnology and Pharmaceutical. Wei Fu is the Founder & Chief Executive Officer at C-Bridge Capital.

## Contacts

5 contacts available for Wei Fu: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/wei-fu?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Pharmaceutical | 4 | 57% |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Product Research | 2 | 29% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series C | 1 | 14% |
| Post-IPO Secondary | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 43% |
| United States | 2 | 29% |
| Singapore | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Everest Medicines | Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients inthe Emerging Market and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in Asia Pacific territories and with leading global pharmaceutical companies. | $6.8M | Post-IPO Secondary | May 14, 2026 |  |
| Hasten | Hasten is a pharmaceutical manufacturing company that integrates R&D, manufacturing, and commercialization, and covers the entire industry chain. They are dedicated to creating China's innovative medical and health company, and they collaborate with key government agencies, medical and health professionals, and industry partners to providehigh-quality solutions, build a health management ecosystem, and benefit more patients. | $315M | Venture - Series Unknown | Apr 20, 2023 |  |
| RVAC Medicines | RVAC Medicines is a mRNA platform company engaged in the research and development of innovative products such as vaccines for diseases. | $140M | Series B | Apr 26, 2022 |  |
| I-Mab Biopharma | I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. . | $220M | Series C | Jun 29, 2018 |  |
| I-Mab Biopharma | I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. . | $220M | Series C | Jun 29, 2018 |  |
| Nuance Biotech | Nuance Biotech is a pharmaceutical company Based In China. | $20M | Series B | Jun 28, 2018 |  |
| Ascletis | Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China'scapital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. | $100M | Series B | Jan 03, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 3 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 2 deals together
- [Hony Capital](https://shizune.co/investors/profile/hony-capital) — VC Fund, 2 deals together
- [HOPU Investment Management Company](https://shizune.co/investors/profile/hopu-fund) — VC Fund, 2 deals together

## About C-Bridge Capital

VC Fund · New York, United States

C-Bridge Capital Partners identifies and unlocks opportunities to drive growth and development across borders. They leverage their expertise in the United States, China and Israel to help their global clients form international strategic alliances that achieve maximum returns. Using their unparalleled network and extensive knowledge, Theyfacilitate cross-border investments and asset formation in the US, China and Israel. They remain involved to monitor and protect their clients’ investment interests.

5 contacts available at C-Bridge Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Wei Fu | Founder & Chief Executive Officer | — |
| Abbas Hussain | Senior Partner | — |
| Christopher Shen | Managing Director | https://shizune.co/investors/profile/christopher-shen |
| Kang Lan | Managing Director | — |
| Lu Yanxiang | Senior Managing Director | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Wei Fu invest in?

Wei Fu invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Wei Fu?

Public channels for Wei Fu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Wei Fu last invest?

The most recent investment recorded for Wei Fu closed in May 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co